Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Am J Gastroenterol ; 118(3): 383-385, 2023 03 01.
Article in English | MEDLINE | ID: covidwho-2264449
3.
Curr Opin Gastroenterol ; 37(6): 619-624, 2021 11 01.
Article in English | MEDLINE | ID: covidwho-1377994

ABSTRACT

PURPOSE OF REVIEW: This review highlights literature from the past year and explores the impact on current understanding of celiac disease pathogenesis, diagnosis, and management. RECENT FINDINGS: In contrast to earlier clinical trials, recent data suggests that early gluten introduction may protect against the development of celiac disease. Celiac disease is underdiagnosed, associated with high burden of disease and linked to excess mortality risk, yet, there remains considerable uncertainty regarding the utility of mass screening in asymptomatic individuals. The gut microbiome is increasingly implicated in celiac disease pathogenesis, although the exact mechanism is undefined. Probiotics have been proposed as a disease-modifying option for celiac disease but most studies assessing efficacy are of low-quality. Patients with celiac disease do not appear to be at increased risk of contracting or developing adverse outcomes from COVID-19. Little is known about the pathogenesis of nonceliac gluten sensitivity; however, recent findings suggest an autoimmune basis for the condition. SUMMARY: Current understanding of celiac disease continues to advance, though significant knowledge gaps remain. Large, rigorous, prospectively designed studies are needed to further characterize celiac disease pathogenesis, management and therapeutic options.


Subject(s)
COVID-19 , Celiac Disease , Celiac Disease/diagnosis , Celiac Disease/therapy , Diet, Gluten-Free , Glutens , Humans , SARS-CoV-2
4.
Clin Med (Lond) ; 21(2): 127-130, 2021 03.
Article in English | MEDLINE | ID: covidwho-1357645

ABSTRACT

Coeliac disease (CD) is a common autoimmune-mediated gluten sensitive enteropathy, with a prevalence of around 1%. While the incidence of CD has increased over the last 2 decades, many cases still remain undiagnosed. The presentation of CD is variable and can be subtle, with it being important to explore both gastrointestinal and extra-intestinal features. The cornerstone of management is adherence to a strict gluten free diet, which requires support and education from an expert gastrointestinal dietitian. Persisting symptoms in individuals requires re-evaluation, with repeat duodenal biopsies sometimes required. Refractory CD affects a small subset of individuals with CD, requiring specialist input.


Subject(s)
Celiac Disease , Biopsy , Celiac Disease/diagnosis , Celiac Disease/epidemiology , Celiac Disease/therapy , Diet, Gluten-Free , England/epidemiology , Humans , State Medicine
5.
Dig Liver Dis ; 53(10): 1221-1227, 2021 10.
Article in English | MEDLINE | ID: covidwho-1326970

ABSTRACT

The purpose of the present document is to provide detailed information on the correct and optimal use of digital media to ensure continuity of care for gastroenterological patients in everyday clinical practice, in health emergencies and/or when the patient cannot reach the hospital for other reasons. During the recent COVID-19 pandemic, telemedicine has allowed many patients with chronic diseases to access remote care worldwide, proving to be the ideal solution to overcome restrictions and carry out non-urgent routine follow-ups on chronic patients. The COVID-19 pandemic has therefore made organizational and cultural renewal essential for the reorganization of healthcare in order to ensure greater continuity of care with a minimum risk of spreading the virus to users, practitioners and their families. These AIGO recommendations are intended to provide Italian gastroenterologists with a tool to use this method appropriately, in compliance with current legislation, in particular the proper approach and procedures for conducting a remote examination using a video conferencing tool, the so-called televisit. In the near future, telemedicine may contribute to a possible reorganization of healthcare systems, through innovative care models focusing on the citizen and facilitating access to services throughout the entire Country.


Subject(s)
COVID-19/prevention & control , Endoscopy, Gastrointestinal , Gastroenterology , SARS-CoV-2 , Telemedicine , Celiac Disease/therapy , Chronic Disease , Humans , Inflammatory Bowel Diseases/therapy , Italy , Liver Diseases/therapy , Societies, Medical
6.
Eur Rev Med Pharmacol Sci ; 25(12): 4400-4404, 2021 06.
Article in English | MEDLINE | ID: covidwho-1296350

ABSTRACT

OBJECTIVE: Celiac disease (CD) is an autoimmune disorder, characterized by increased susceptibility to bacterial and viral infections. Therefore, the CD patients could be exposed to an increased risk of contracting SARS-CoV-2, a virus for which the WHO declared a pandemic status in March 2020. This study aims to investigate the incidence of SARS-CoV-2 infection in CD patients, to assess the impact of CD on the risk of contracting this virus. PATIENTS AND METHODS: This retrospective multicentric cohort study evaluated 542 celiac patients, who answered a questionnaire concerning both the underlying disease (adherence to the gluten-free diet, residual symptoms) and the possible SARS-CoV-2 infection (swab outcome, presence and characteristics of symptoms and type of treatment received), referring to the period between 20th January 2020 and 27th October 2020. RESULTS: Five patients (0.92%) tested positive; of these, 2 were asymptomatic and 3 developed symptoms of COVID-19. The incidence of SARS-CoV-2 infection in CD patients was not significantly different from the general population. The ratio of positive/diagnostic swabs tends to be higher in CD patients than in the general population (IR: 0.15; 0.06; p=0.06), whereas the number of subjects who performed the swab in this group is significantly lower (IR: 0.06; 0.15; p<0.001). CONCLUSIONS: Although CD patients are more susceptible to infections, the incidence of SARS-CoV-2 infection in our sample was not significantly different from the general population. However, the positive/diagnostic swabs ratio seems to be higher, probably also due to the lower number of patients tested.


Subject(s)
COVID-19/diagnosis , COVID-19/epidemiology , Celiac Disease/diagnosis , Celiac Disease/epidemiology , COVID-19/therapy , COVID-19 Testing/methods , Celiac Disease/therapy , Cohort Studies , Diet, Gluten-Free/methods , Humans , Italy/epidemiology , Retrospective Studies
7.
Medicina (Kaunas) ; 56(9)2020 Aug 27.
Article in English | MEDLINE | ID: covidwho-738923

ABSTRACT

The positive impact of probiotic strains on human health has become more evident than ever before. Often delivered through food, dietary products, supplements, and drugs, different legislations for safety and efficacy issues have been prepared. Furthermore, regulatory agencies have addressed various approaches toward these products, whether they authorize claims mentioning a disease's diagnosis, prevention, or treatment. Due to the diversity of bacteria and yeast strains, strict approaches have been designed to assess for side effects and post-market surveillance. One of the most essential delivery systems of probiotics is within food, due to the great beneficial health effects of this system compared to pharmaceutical products and also due to the increasing importance of food and nutrition. Modern lifestyle or various diseases lead to an imbalance of the intestinal flora. Nonetheless, as the amount of probiotic use needs accurate calculations, different factors should also be taken into consideration. One of the novelties of this review is the presentation of the beneficial effects of the administration of probiotics as a potential adjuvant therapy in COVID-19. Thus, this paper provides an integrative overview of different aspects of probiotics, from human health care applications to safety, quality, and control.


Subject(s)
Coronavirus Infections/prevention & control , Dietary Supplements/standards , Gastrointestinal Diseases/therapy , Liver Diseases/therapy , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Probiotics/therapeutic use , Betacoronavirus , COVID-19 , Celiac Disease/therapy , Clostridium Infections/therapy , Constipation/therapy , Coronavirus Infections/drug therapy , Coronavirus Infections/therapy , Depressive Disorder/therapy , Diverticular Diseases/therapy , Dysentery/therapy , Enterocolitis, Necrotizing/therapy , Fermented Foods , Food Hypersensitivity/therapy , Helicobacter Infections/therapy , Hepatic Encephalopathy/therapy , Humans , Inflammatory Bowel Diseases/therapy , Non-alcoholic Fatty Liver Disease/therapy , Pneumonia, Viral/therapy , Probiotics/adverse effects , Probiotics/standards , Quality Control , SARS-CoV-2 , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL